SIMVASTATIN INHIBITS THE OXIDATION OF LOW-DENSITY LIPOPROTEINS BY ACTIVATED HUMAN MONOCYTE-DERIVED MACROPHAGES

被引：173

作者：

GIROUX, LM ^{[1
]}

DAVIGNON, J ^{[1
]}

NARUSZEWICZ, M ^{[1
]}

机构：

[1] CLIN RES INST MONTREAL, HYPERLIPIDEMIA & ATHEROSCLEROSIS RES GRP, 110 PINE AVE W, MONTREAL H2W 1R7, QUEBEC, CANADA

来源：

BIOCHIMICA ET BIOPHYSICA ACTA | 1993年 / 1165卷 / 03期

关键词：

SIMVASTATIN; MACROPHAGE; OXIDIZED LDL; LDL;

D O I：

10.1016/0005-2760(93)90145-Y

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Human monocyte-derived macrophages treated with increasing concentrations of the HMG-CoA reductase inhibitor, simvastatin, showed a dose-dependent decrease in superoxide formation in response to activation by phorbol myristate acetate. As a consequence, they oxidized LDL much less than untreated cells. Addition of exogenous mevalonic acid to simvastatin-treated macrophages restored their ability for superoxide production and for oxidative modification of LDL. These results indicate that simvastatin might prevent atherosclerosis by additional mechanisms besides its hypocholesterolemic activity.

引用

页码：335 / 338

页数：4

共 28 条

[1]

AVIRAM M, 1991, EUR J CLIN CHEM CLIN, V29, P657

[2] LOVASTATIN INHIBITS LOW-DENSITY-LIPOPROTEIN OXIDATION AND ALTERS ITS FLUIDITY AND UPTAKE BY MACROPHAGES - INVITRO AND INVIVO STUDIES [J].